Nitinotes Announces Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center Clinical Site Activation in the EASE™ IDE Trial

Trial StartEndoZip™ Automated Suturing SystemPositive

AI Analysis

Summary

Nitinotes announced activation of Weill Cornell Medicine as a clinical site in the EASE™ IDE Trial for its EndoZip™ Automated Suturing System, with the first study patient treated by Dr. Reem Sharaiha.

Clinical Trial Data

Patients

Outcome Details

First study patient treated in EASE™ IDE Trial

Importance:4/10

Sentiment:

0.30

clinical trialmedical deviceendoscopyobesity treatmentIDE trial

Related Companies

$SHWZ $MDCE $TRAX

Read the original article

Published by PR Newswire Pharma on August 11, 2026 1:30 PM

Read Original